Publisher
Springer Science and Business Media LLC
Subject
Cellular and Molecular Neuroscience,Clinical Neurology
Reference10 articles.
1. Cummings, J. L. et al. ABBY: a phase 2 randomized trial of crenezumab in mild to moderate Alzheimer disease. Neurology 90, e1889–e1897 (2018).
2. Honig, L. S. et al. Trial of solanezumab for mild dementia due to Alzheimer’s disease. N. Engl. J. Med. 378, 321–330 (2018).
3. Rogers, M. B. A4 Researchers raise solanezumab dose, lengthen the trial. alzforum
https://www.alzforum.org/news/research-news/a4-researchers-raise-solanezumab-dosage-lengthen-trial
(2017).
4. McCaffrey, P. Second look at BAN2401 data still positive, despite snafu. alzforum
https://www.alzforum.org/news/conference-coverage/second-look-ban2401-data-still-positive-despite-snafu
(2018).
5. Sevigny, J. et al. The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease. Nature 537, 50–56 (2016).
Cited by
34 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献